Safety and Immunogenicity of NVX-CoV2705

This study is a Phase 3 trial designed to check the safety and immune response to a new Omicron JN.1 COVID-19 vaccine. Study researchers will give a single dose of this vaccine, called NVX-CoV2705, to approximately 120 participants. This includes adults aged 65 and older, and individuals aged 12 to 64 who have existing health conditions that put them at high risk for severe COVID-19. All participants must have received a previous COVID-19 vaccine at least 90 days before joining this study. Study researchers will be closely monitoring participants for their immune response for 28 days and collecting safety data for 180 days after vaccination.

NCT Number	NCT07079670
Lead Sponsor	Sanofi Collaborators: Novavax
Conditions	COVID-19, SARS-CoV-2 Infection
Enrollment	676 participants
Start Date	2025-10-09
Primary Completion	2026-01-12 (estimated)
Study Completion	2026-05-11 (estimated)
Updated on ClinicalTrials.gov	2026-06-05